PURE Bioscience, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PURE research report →
About the company
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.
- CEO
- Robert F. Bartlett
- IPO
- 1996
- Employees
- 12
- HQ
- El Cajon, CA, US
Price Chart
- Market Cap
- $6.61M
- P/E
- -3.05
- P/S
- 2.73
- P/B
- -1.14
- EV/EBITDA
- 65.51
- Div Yield
- 0.00%
- Gross Margin
- 53803.55%
- Op Margin
- -79.11%
- Net Margin
- -91.04%
- ROE
- 38.73%
- ROIC
- -291.19%
- Revenue
- $2.20M · 12.18%
- Net Income
- $-2,399,000 · 28.39%
- EPS
- $-0.02 · 28.43%
- Op Income
- $-2,272,000
- FCF YoY
- -79512.80%
- 52W High
- $0.14
- 52W Low
- $0.04
- 50D MA
- $0.07
- 200D MA
- $0.07
- Beta
- 0.21
- Avg Volume
- 33.88K
Get TickerSpark's AI analysis on PURE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 0 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 45,000 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 300,000 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 155,000 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 45,000 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 70,000 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 90,000 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 150,000 |
| Aug 20, 24 | Myers Thomas Richard | other | 155,000 |
| Aug 20, 24 | Rendall David | other | 125,000 |
Our PURE coverage
Recent articles, reports, and earnings notes.
No research on PURE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PURE report →Similar companies
Peers in the same neighborhood.